Phaseline

Companies › Clene Nanomedicine

Clene Nanomedicine: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Neurology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
CNM-Au8
Gold nanocrystals for bioenergetic catalysis
–Phase 2Amyotrophic Lateral Sclerosis–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05299658CNM-Au8Phase 2Amyotrophic Lateral SclerosisNeurologyJun 2026

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Aptinyx Neuron23 Bial R&D Investments SHINKEI Therapeutics NeuroTherapia

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.